ID   KM3/BTZ
AC   CVCL_GZ66
DR   ChEMBL-Cells; CHEMBL4483150
DR   ChEMBL-Targets; CHEMBL4483251
DR   PubChem_Cell_line; CVCL_GZ66
DR   Wikidata; Q54900070
RX   DOI=10.1182/blood.V124.21.5226.5226;
RX   DOI=10.6040/j.issn.1671-7554.2013.02.007;
CC   Population: Chinese.
CC   Selected for resistance to: ChEBI; CHEBI_52717; Bortezomib (Velcade).
CC   Cell type: Plasma cell; CL=CL_0000786.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_GZ65 ! KM3 [Human myeloma]
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 14-08-25; Version: 10
//
RX   DOI=10.1182/blood.V124.21.5226.5226;
RA   Wang, Lu-Qun
RA   Liu, Qiong
RA   Li, Hao
RA   Li, Li-Zhen
RA   Wang, Xin
RT   "The establishment of bortezomib resistant myeloma cell line KM3/BTZ
RT   and explore the resistance mechanism.";
RL   Blood 124 Suppl. 1:5226-5226(2014).
//
RX   DOI=10.6040/j.issn.1671-7554.2013.02.007;
RA   Pu, Ye-Di
RA   Li, Li-Zhen
RA   Mao, Dao-Xin
RA   Dong, Ke
RA   Zhao, Chuan-Li
RA   Song, Qiang
RA   Wang, Lu-Qun
RT   "Establishment of a bortezomib-resistant cell line KM3/BTZ of human
RT   multiple myeloma.";
RL   Shandong Da Xue Xue Bao Li Xue Ban 51:33-36(2013).
//